Ozempic and Wegovy: What the Trials Actually Showed
Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024

Search
10 stories for“wegovy semaglutide”
Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024

Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024

Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025

The agency's first global guideline on child obesity backs structured eating, activity and behaviour programmes, and allows medicines for teenagers only after those have failed.
Oct 7, 2026

Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.
Aug 11, 2026

Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024

Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
May 15, 2024

Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024

A study of 2,031 young patients aged 10 to 17 found vitamin D deficiency in 12.4 per cent within a year of starting a GLP-1 drug, while fewer than a quarter had any nutrition counselling visit in the same period.
Sep 26, 2026
